Agenus to participate in b. riley securities' oncology investor conference

Lexington, mass., jan. 19, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that dr. jennifer buell, president and coo of agenus, and dr. steven o'day, cmo of agenus, will participate in b. riley securities' oncology investor conference on january 20-21, 2021.
AGEN Ratings Summary
AGEN Quant Ranking